Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials.

[1]  M. Momoi,et al.  Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS , 2004, Brain and Development.

[2]  P. Sutphin,et al.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.

[3]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[4]  Chi V Dang,et al.  Multifaceted roles of glycolytic enzymes. , 2005, Trends in biochemical sciences.

[5]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[6]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[7]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells , 1997, The Journal of Biological Chemistry.

[8]  E. Kandel,et al.  Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. , 2001, Genes & development.

[9]  P. Stacpoole.  Review of the pharmacologic and therapeutic effects of diisopropylammonium dichloroacetate (DIPA). , 1969, The Journal of clinical pharmacology and the journal of new drugs.

[10]  Manuel Hidalgo,et al.  Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. , 2005, Cancer research.

[11]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[12]  A. Halestrap,et al.  A pore way to die , 2005 .

[13]  L. B. Chen,et al.  Mitochondrial membrane potential in living cells. , 1988, Annual review of cell biology.

[14]  Alexander Kamb,et al.  Why is cancer drug discovery so difficult? , 2007, Nature Reviews Drug Discovery.

[15]  R. A. Howlett,et al.  Effects of dichloroacetate infusion on human skeletal muscle metabolism at the onset of exercise. , 1999, The American journal of physiology.

[16]  C. Thompson,et al.  Cell metabolism in the regulation of programmed cell death , 2002, Trends in Endocrinology & Metabolism.

[17]  T. Mak,et al.  Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era? , 2007, Science's STKE.

[18]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells , 2001, The Journal of Biological Chemistry.

[19]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[20]  J. Yuan,et al.  Activation of K+ channels: an essential pathway in programmed cell death. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[21]  D. Theriaque,et al.  Controlled Clinical Trial of Dichloroacetate for Treatment of Congenital Lactic Acidosis in Children , 2006, Pediatrics.

[22]  G. Kroemer,et al.  The mitochondrion in apoptosis: how Pandora's box opens , 2001, Nature Reviews Molecular Cell Biology.

[23]  J. Hoek,et al.  Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. , 2005, Cancer research.

[24]  Wengang Cao,et al.  Dichloroacetate (DCA) sensitizes both wild‐type and over expressing Bcl‐2 prostate cancer cells in vitro to radiation , 2008, The Prostate.

[25]  S. Dimauro,et al.  Dichloroacetate causes toxic neuropathy in MELAS , 2006, Neurology.

[26]  A. Hutson,et al.  Efficacy of Dichloroacetate as a Lactate‐Lowering Drug , 2003, Journal of clinical pharmacology.

[27]  H. Savolainen.  Dichloroacetate causes toxic neuropathy in MELAS: A randomized, controlled clinical trial , 2006, Neurology.

[28]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[29]  N. Munshi,et al.  Dichloroacetate induces apoptosis in endometrial cancer cells. , 2008, Gynecologic oncology.

[30]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[31]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[32]  P. Stacpoole.  The pharmacology of dichloroacetate. , 1989, Metabolism: clinical and experimental.

[33]  M. Holness,et al.  Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. , 2003, American journal of physiology. Endocrinology and metabolism.

[34]  G. Heigenhauser,et al.  Effects of PDH activation by dichloroacetate in human skeletal muscle during exercise in hypoxia. , 2000, American journal of physiology. Endocrinology and metabolism.